Phreesia
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Phreesia (PHR) | 708.23M | 63.39 | 1.90 | 0.00% |
| Veeva Systems (VEEV) | 43.10B | 43.64 | 5.80 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.50B | 33.78 | 5.75 | 0.00% |
| Tempus AI (TEM) | 9.86B | -50.98 | 19.70 | 0.00% |
| Hinge Health (HNGE) | 8.60B | 51.68 | 28.71 | 0.00% |
| HealthEquity (HQY) | 7.84B | 34.21 | 3.94 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 44.5% below Morningstar's fair value estimate.
Fair value
Phreesia Inc may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 23% discount to our quantitative fair value estimate of $16.49 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 6.4, which lies in the bottom 20% compared with peers globally. Relative to the company's EBITDA, the enterprise value of the business is low, which contributes to our view that shares are cheap.
The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's enterprise value to free cash flow ratio of 11.6, a core component of profitability, falls in the bottom 30% compared with global peers. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. This characteristic further promotes our favorable price/fair value ratio.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Phreesia discussion 0 comments